Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-12-25 17:00Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 4, 2024, to October 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Skye securities during the specified Class Period [2]. - The complaint alleges that the defendants made materially false and misleading statements regarding Skye's business, operations, and prospects [3]. - Specific allegations include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [8]. Group 2: Investor Participation - Investors who suffered losses in Skye have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [4]. Group 3: Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5]. - The firm emphasizes restoring investor capital and ensuring corporate accountability to maintain market integrity [5].